EAGAN, Minn.--(BUSINESS WIRE)--Biothera’s Imprime PGG™ increased the effectiveness of Avastin® (bevacizumab), a monoclonal antibody approved for the treatment of metastatic colorectal, breast and non-small cell lung cancer, according to a new preclinical study published in the current issue of Clinical Cancer Research.
